Here are the top stories from the last week:

Industry Updates

MAHA report on children's health faces backlash over flawed science
The report aims to improve children's health, but critics say it relies on flawed science and weak regulation.
Read article »

Lewis Drug is joining Sanford Health
Lewis Drug, which includes 60 locations in South Dakota, Iowa, and Minnesota, is joining Sanford Health. This partnership includes the co-location of 11 Sanford Health clinics with Lewis Drug pharmacies, aiming to make it easier for patients to access prescription and non-prescription medications.
Read article »

Study: How Stress and Diet Disrupt a Brain Circuit to Increase Diabetes Risk
Researchers uncover a brain circuit linking stress to increased blood sugar, revealing insights into stress's role in type 2 diabetes (T2D) development.
Read article »

CHPA honors Dr. Greg Collier with 2025 Career Achievement Award
"Dr. Collier's decades of dedication, vision, and leadership embody the spirit of this award," said CHPA President and CEO Scott Melville.
Read article »

NCPA applauds FTC pick for associate director of healthcare
Emma Mittelstaedt Burnham is an experienced antitrust enforcer, exactly what patients and providers need to go up against PBMs and insurers.
Read article »

Treatment & Technology Updates

Sandoz reaches agreement with Regeneron related to aflibercept biosimilar
Sandoz has reached an agreement with Regeneron that allows Sandoz to enter the U.S. market with a biosimilar version of Eylea, known as Enzeevu, by the end of2026. This agreement clears the path for the launch of Enzeevu, potentially earlier under certain conditions.
Read article »

Pfizer–BioNTech COVID-19 Vaccine Elicits Robust Responses in High-Risk Adults
According to phase 3 trial results, Pfizer-BioNTech's LP.8.1-adapted COVID-19vaccine demonstrated significant immune responses in older adults and individuals at high risk for severe COVID-19.
Read article »

Switching from Humira to Biosimilar Did Not Affect Disease Control, Quality of Life in IBD
Patients with inflammatory bowel disease (IBD) who switched to the biosimilar reported adverse events, but these are believed to stem from health anxiety.
Read article »

Amneal gets FDA approval of sodium oxybate oral solution
Sodium oxybate oral solution is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy.
Read article »

‍